HPV L1 VLP vaccine profiles
| Gardasil™ | Cervarix™ | |
|---|---|---|
| HPV, human papillomavirus; VLP, virus-like particle. | ||
| L1 VLP antigens | HPV6 20 μg | HPV16 20 μg |
| HPV11 40 μg | HPV18 20 μg | |
| HPV16 40 μg | ||
| HPV18 20 μg | ||
| Expression system | Yeast [S cerevisiae] | Baculovirus |
| Adjuvant | Proprietary aluminum hydroxyphosphate sulfate (225 ug) | ASO4 |
| Aluminum hydroxide (500 μg) plus | ||
| 50 μg 3-deacylated monophosphoryl lipid A | ||
| Injection volume | 0.5 ml i.m. | 0.5 i.m. |
| Immunisation schedule | 0, 2 and 6 months | 0, 1 and 6 months |
| Adolescent safety/immunogenicity bridging trials | Females and males 9–15 years | Females 10–14 years |
| Males 10–18 years (in progress) | ||
| Licensed | License application made | |